Huron Consulting Group Inc.

Huron Announces Third Quarter 2026 Financial Results and Raises 2026 Adjusted Diluted EPS Guidance

Huron reported record Q3 2026 revenues before reimbursable expenses of $482.5 million, up 11.6% year-over-year, with 6.7% organic growth excluding acquisitions. Adjusted diluted EPS rose 24.8% to $2.62; GAAP diluted EPS was $1.75, including a $0.36 unfavorable impact from a $5.9 million non-cash credit loss on a convertible debt investment. The company raised its full-year adjusted EPS guidance midpoint to $9.30, narrowed FY2026 RBR guidance to $1.855-$1.885 billion, and increased its buyback authorization from $900 million to $1.1 billion, extended through 2028. Management cited growth across all three segments and double-digit growth in Consulting/Managed Services and Digital, with a strong backlog supporting confidence in continued 2027 growth.

•6h ago

Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600

Huron Consulting Group will join the S&P SmallCap 600 before the open on Tuesday, November 3, one day later than the originally announced November 2 effective date. S&P DJI revised the date due to a special dividend ex-date announcement tied to Indivior Pharmaceuticals' pending acquisition of Supernus Pharmaceuticals, which frees HURN's index slot. Index inclusion typically triggers passive-fund buying of HURN shares ahead of the effective date.

•6d ago

Huron Announces Record Second Quarter 2026 Financial Results and Increases 2026 Guidance

Huron reported record Q2 2026 revenue of $465.6 million, up 15.7% year-over-year, driven by organic growth and acquisitions. Profitability expanded significantly, with net income increasing 60.8% to $31.2 million and Adjusted EBITDA rising 19.9% to $72.6 million. The company returned $208.6 million to shareholders in the first half of 2026 via share buybacks and raised its full-year 2026 guidance for RBR, Adjusted EBITDA margin, and Adjusted EPS.

•3mo ago

Huron Elects Dr. L. Thomas Richards to Board of Directors

Huron elected Dr. L. Thomas Richards to its Board of Directors, effective July 23, 2026, increasing the board size to 10 members. Dr. Richards is a former investment banker, physician, and executive who most recently served as Chair of WittKieffer, bringing deep expertise in life sciences and corporate governance. Chairman Hugh Sawyer noted that Richards' background in capital markets and technology adoption will support Huron's growth strategy and long-term value creation.

•3mo ago

Huron Leaders Named 2026 Consulting Magazine Top Consultants

Huron announced that three of its senior leaders were recognized by Consulting Magazine as 2026 Top Consultants. John DiDonato received the Lifetime Achievement Award for a career spanning four decades, while Paul Praveen and Andy Waldeck were honored for their work in global operations and strategy, respectively. CEO Mark Hussey noted that the awards reflect the firm's depth of expertise and leadership in driving value for clients.

•4mo ago

Huron Announces Election of Shoshana Vernick to Board of Directors

Huron elected Shoshana Vernick to its Board of Directors, effective June 19, 2026, bringing the total number of board members to nine. Ms. Vernick is the co-founder and managing partner of Avathon Capital, a private equity firm focused on the education sector, bringing expertise in technology-enabled growth and capital markets.

•4mo ago

Huron Acquires RelateCare to Strengthen Patient Access and Care Coordination Capabilities

Huron Consulting Group (HURN) has acquired RelateCare, a provider of AI-enabled clinical and patient access solutions. The deal strengthens Huron’s healthcare managed services portfolio, combining its care transformation expertise with RelateCare’s technology-driven patient scheduling and triage capabilities. Transaction terms were not disclosed, but RelateCare will be reported within Huron’s Healthcare operating segment.

•5mo ago

Huron Announces First Quarter 2026 Financial Results and Affirms Full Year 2026 Guidance

Huron reported Q1 2026 revenue before reimbursable expenses (RBR) of $443.7 million, up 12.1% year-over-year, driven by record performance in its Healthcare segment and solid growth in Commercial. Adjusted EBITDA surged 21.9% to $50.6 million, while adjusted diluted EPS rose 3.0% to $1.73, supported by margin expansion. The company returned $155.5 million to shareholders through the repurchase of 1.1 million shares, representing 6.5% of the outstanding float, while affirming full-year guidance.

•5mo ago